News and Announcements
Proteomics Gaining Strong Traction in Analytical Services
- Published May 20, 2016 1:27PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
20th May 2016, ASX Announcement
- PILL has generated monthly revenues of $100,000 in each of March and April (a 60% uplift on the previous monthly average).
- Several recent contract wins underscore ongoing activity.
- Growth driven by biosimilars (generic protein drug) market as the sector seeks to replicate the multiple billion dollar blockbuster biopharmaceutical drugs that are coming off patent.
- PILL has one of the few global ISO 17025 laboratories accredited to accurately analyse the make-up of biosimilar drugs as being like-for-like with the brand-name drugs they seek to replace.
- Present growth substantiates business model as PILL seeks to become cash flow positive.
Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to provide the following update on the growth of its analytical services operations.
PILL’s analytical services generate a regular ongoing revenue stream by providing a fee-for-service offering in proteomics, protein characterisation, biosimilars and biomarker diversity.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
